To read the full story, subscribe or sign in.

Biogen To Pay Schering $55M Bringing MS Dispute To End

Feb. 4, 2003

With an appeals court decision that Biogen Inc. must pay another $55 million to Schering AG in their patent fight over beta interferon, the longstanding dispute apparently has been laid to rest. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Nov. 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 7, 2025.

Photo of a red fox head in the shadows with a black background,

Enara validates first dark antigen cancer target, unveils bispecific T-cell engager

BioWorld

Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated regions of the dark genome, describing...

Ulipristal reprograms breast tissue, cutting cancer-prone cells

BioWorld

Blocking progesterone receptor (PR) activity has long been viewed as a possible approach to breast cancer prevention. Historically, most supporting evidence came...

Mwyngil Therapeutics in-licenses GPR75 modulators

BioWorld Science

Mwyngil Therapeutics Inc. has in-licensed several lead GPR75 modulator molecules and a proprietary cell-surface discovery platform from Expert Systems Inc.